PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
BBIO vs. ROIV
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between BBIO and ROIV is 0.35, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

BBIO vs. ROIV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BridgeBio Pharma, Inc. (BBIO) and Roivant Sciences Ltd. (ROIV). The values are adjusted to include any dividend payments, if applicable.

-10.00%0.00%10.00%20.00%30.00%40.00%50.00%SeptemberOctoberNovemberDecember2025February
38.31%
-6.97%
BBIO
ROIV

Key characteristics

Sharpe Ratio

BBIO:

0.06

ROIV:

-0.19

Sortino Ratio

BBIO:

0.53

ROIV:

-0.06

Omega Ratio

BBIO:

1.06

ROIV:

0.99

Calmar Ratio

BBIO:

0.05

ROIV:

-0.21

Martin Ratio

BBIO:

0.11

ROIV:

-0.68

Ulcer Index

BBIO:

30.13%

ROIV:

8.35%

Daily Std Dev

BBIO:

56.86%

ROIV:

30.47%

Max Drawdown

BBIO:

-92.80%

ROIV:

-79.22%

Current Drawdown

BBIO:

-50.95%

ROIV:

-21.01%

Fundamentals

Market Cap

BBIO:

$6.71B

ROIV:

$7.62B

EPS

BBIO:

-$2.42

ROIV:

-$1.00

Total Revenue (TTM)

BBIO:

$216.02M

ROIV:

$97.56M

Gross Profit (TTM)

BBIO:

$212.93M

ROIV:

$86.85M

EBITDA (TTM)

BBIO:

-$201.78M

ROIV:

$4.44B

Returns By Period

In the year-to-date period, BBIO achieves a 29.34% return, which is significantly higher than ROIV's -9.72% return.


BBIO

YTD

29.34%

1M

5.03%

6M

38.31%

1Y

-4.62%

5Y*

0.29%

10Y*

N/A

ROIV

YTD

-9.72%

1M

-4.22%

6M

-6.97%

1Y

-7.85%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

BBIO vs. ROIV — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBIO
The Risk-Adjusted Performance Rank of BBIO is 4545
Overall Rank
The Sharpe Ratio Rank of BBIO is 4646
Sharpe Ratio Rank
The Sortino Ratio Rank of BBIO is 4545
Sortino Ratio Rank
The Omega Ratio Rank of BBIO is 4343
Omega Ratio Rank
The Calmar Ratio Rank of BBIO is 4747
Calmar Ratio Rank
The Martin Ratio Rank of BBIO is 4545
Martin Ratio Rank

ROIV
The Risk-Adjusted Performance Rank of ROIV is 3131
Overall Rank
The Sharpe Ratio Rank of ROIV is 3535
Sharpe Ratio Rank
The Sortino Ratio Rank of ROIV is 2929
Sortino Ratio Rank
The Omega Ratio Rank of ROIV is 2929
Omega Ratio Rank
The Calmar Ratio Rank of ROIV is 3232
Calmar Ratio Rank
The Martin Ratio Rank of ROIV is 3131
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

BBIO vs. ROIV - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Roivant Sciences Ltd. (ROIV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for BBIO, currently valued at 0.06, compared to the broader market-2.000.002.004.000.06-0.19
The chart of Sortino ratio for BBIO, currently valued at 0.53, compared to the broader market-6.00-4.00-2.000.002.004.006.000.53-0.06
The chart of Omega ratio for BBIO, currently valued at 1.06, compared to the broader market0.501.001.502.001.060.99
The chart of Calmar ratio for BBIO, currently valued at 0.06, compared to the broader market0.002.004.006.000.06-0.21
The chart of Martin ratio for BBIO, currently valued at 0.11, compared to the broader market0.0010.0020.0030.000.11-0.68
BBIO
ROIV

The current BBIO Sharpe Ratio is 0.06, which is higher than the ROIV Sharpe Ratio of -0.19. The chart below compares the historical Sharpe Ratios of BBIO and ROIV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.00SeptemberOctoberNovemberDecember2025February
0.06
-0.19
BBIO
ROIV

Dividends

BBIO vs. ROIV - Dividend Comparison

Neither BBIO nor ROIV has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

BBIO vs. ROIV - Drawdown Comparison

The maximum BBIO drawdown since its inception was -92.80%, which is greater than ROIV's maximum drawdown of -79.22%. Use the drawdown chart below to compare losses from any high point for BBIO and ROIV. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%SeptemberOctoberNovemberDecember2025February
-33.55%
-21.01%
BBIO
ROIV

Volatility

BBIO vs. ROIV - Volatility Comparison

BridgeBio Pharma, Inc. (BBIO) has a higher volatility of 19.35% compared to Roivant Sciences Ltd. (ROIV) at 7.10%. This indicates that BBIO's price experiences larger fluctuations and is considered to be riskier than ROIV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%SeptemberOctoberNovemberDecember2025February
19.35%
7.10%
BBIO
ROIV

Financials

BBIO vs. ROIV - Financials Comparison

This section allows you to compare key financial metrics between BridgeBio Pharma, Inc. and Roivant Sciences Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab